![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
SUMMARY Aims: To investigate the effectiveness of N-palmitoylethanolamide (PEA) in the treatment of neuropathic pain due to lumbosciatica. Materials & methods: Patients with neuropathic pain were assigned to standard treatment plus PEA (600 mg/day) or standard treatment for 30 days. Changes in visual analog scale, and score on Oswestry Disability Index and SF-12® Health Survey were assessed at baseline and follow-up. Results: The mean age of the 118 patients evaluated was 48.4 years, and 47 (40.9%) were women. In the group comparison, significantly larger improvements were seen in the PEA group for visual analog scale and the physical component of the SF-12 Health Survey. Conclusion: The addition of PEA to standard treatment shows an improvement in pain relief in patients with neuropathic pain due to lumbosciatica. PEA was well tolerated. Future investigations of the role of PEA in the treatment of neuropathic pain might help to define novel therapeutic strategies for the treatment of this kind of neuropathic pain.
Financial & competing interests disclosure
This study was supported in part by a grant from Angelini (Barcelona, Spain). Angelini was involved as data support in the statistical analysis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
The authors thank Content Ed Net Communications for editorial assistance. Editorial assistance was supported by Angelini Spain.